» Articles » PMID: 26056952

Novel Theranostic Agents for Next-generation Personalized Medicine: Small Molecules, Nanoparticles, and Engineered Mammalian Cells

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2015 Jun 10
PMID 26056952
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Modern medicine is currently undergoing a paradigm shift from conventional disease treatments based on the diagnosis of a generalized disease state to a more personalized, customized treatment model based on molecular-level diagnosis. This uses novel biosensors that can precisely extract disease-related information from complex biological systems. Moreover, with the recent progress in chemical biology, materials science, and synthetic biology, it has become possible to simultaneously conduct diagnosis and targeted therapy (theranostics/theragnosis) by directly connecting the readout of a biosensor to a therapeutic output. These advances pave the way for more advanced and better personalized treatment for intractable diseases with fewer side effects. In this review, we describe recent advances in the development of cutting-edge theranostic agents that contain both diagnostic and therapeutic functions in a single integrated system. By comparing the advantages and disadvantages of each modality, we discuss the future challenges and prospects of developing ideal theranostic agents for the next generation of personalized medicine.

Citing Articles

In Silico Insights Reveal Fibronectin 1 as a Theranostic Marker in Gastric Cancer.

Millapan T, Gutierrez A, Rosas K, Buchegger K, Ili C, Brebi P Int J Mol Sci. 2024; 25(20).

PMID: 39456895 PMC: 11507984. DOI: 10.3390/ijms252011113.


Exploring the Potential of Nanogels: From Drug Carriers to Radiopharmaceutical Agents.

Kubeil M, Suzuki Y, Casulli M, Kamal R, Hashimoto T, Bachmann M Adv Healthc Mater. 2023; 13(1):e2301404.

PMID: 37717209 PMC: 11468994. DOI: 10.1002/adhm.202301404.


Novel Salinomycin-Based Paramagnetic Complexes-First Evaluation of Their Potential Theranostic Properties.

Pashkunova-Martic I, Kukeva R, Stoyanova R, Pantcheva I, Dorkov P, Friske J Pharmaceutics. 2022; 14(11).

PMID: 36365139 PMC: 9692412. DOI: 10.3390/pharmaceutics14112319.


The analytical and biomedical applications of carbon dots and their future theranostic potential: A review.

Ross S, Wu R, Wei S, Ross G, Chang H J Food Drug Anal. 2022; 28(4):677-695.

PMID: 35696139 PMC: 9261808. DOI: 10.38212/2224-6614.1154.


Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous delivery of tyrosine kinase inhibitors and kinase activity biosensors.

Bofinger R, Weitsman G, Evans R, Glaser M, Sander K, Allan H Nanoscale. 2021; 13(44):18520-18535.

PMID: 34730152 PMC: 8601123. DOI: 10.1039/d1nr02770k.